CR20230402A - Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer - Google Patents
Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancerInfo
- Publication number
- CR20230402A CR20230402A CR20230402A CR20230402A CR20230402A CR 20230402 A CR20230402 A CR 20230402A CR 20230402 A CR20230402 A CR 20230402A CR 20230402 A CR20230402 A CR 20230402A CR 20230402 A CR20230402 A CR 20230402A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- kras
- methyltransferases
- treating
- preventing cancer
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 14
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 102000011787 Histone Methyltransferases Human genes 0.000 abstract 2
- 108010036115 Histone Methyltransferases Proteins 0.000 abstract 2
- 229940124785 KRAS inhibitor Drugs 0.000 abstract 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 abstract 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 abstract 2
- 229940126638 Akt inhibitor Drugs 0.000 abstract 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 229940125431 BRAF inhibitor Drugs 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 229940126204 KRAS G12D inhibitor Drugs 0.000 abstract 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 abstract 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 abstract 1
- 229940124647 MEK inhibitor Drugs 0.000 abstract 1
- 102000016397 Methyltransferase Human genes 0.000 abstract 1
- 108060004795 Methyltransferase Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 239000012270 PD-1 inhibitor Substances 0.000 abstract 1
- 239000012668 PD-1-inhibitor Substances 0.000 abstract 1
- 239000012271 PD-L1 inhibitor Substances 0.000 abstract 1
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940126271 SOS1 inhibitor Drugs 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229940125399 kras g12c inhibitor Drugs 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229940121655 pd-1 inhibitor Drugs 0.000 abstract 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 239000003197 protein kinase B inhibitor Substances 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 102220014328 rs121913535 Human genes 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Esta divulgación se refiere a combinaciones farmacéuticas para tratar y/o prevenir el cáncer y métodos y usos de los mismos. Más concretamente, se proporciona una combinación farmacéutica compuesta por un inhibidor de SOS1 y un ingrediente activo adicional seleccionado entre un inhibidor de KRAS, como un inhibidor de KRAS G12C y un inhibidor de KRASG12D, un inhibidor de KRAS G13C y un inhibidor de panKRAS; un inhibidor de EGFR; un inhibidor de ERK1/2; un inhibidor de BRAF; un inhibidor pan-RAF; un inhibidor de MEK; un inhibidor de AKT; un inhibidor de SHP2; inhibidor de las proteínas arginina metiltransferasas (PRMT), como un inhibidor de PRMT5 y un inhibidor de PRMT tipo 1; un inhibidor de PI3K; un inhibidor de la quinasa dependiente de ciclina (CDK) como el inhibidor de CDK4/6; un inhibidor de FGFR; un inhibidor de c-Met; un inhibidor de RTK; un inhibidor de la tirosina cinasa no receptor; un inhibidor de histonas metiltransferasas (HMT); un inhibidor de las metiltransferasas de ADN (DNMT); un inhibidor de la quinasa de adhesión focal (FAK); un inhibidor de la tirosina cinasa Bcr-Abl; un inhibidor de mTOR; un inhibidor de PD1; un inhibidor de PD-L1; Inhibidor de CTLA4; y agentes quimioterapéuticos como gemcitabina, doxorrubicina, cisplatino, carboplatino, paclitaxel, docetaxel, topotecán, irinotecán y temozolomida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121002487 | 2021-01-19 | ||
PCT/IB2022/050415 WO2022157629A1 (en) | 2021-01-19 | 2022-01-19 | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230402A true CR20230402A (es) | 2023-11-21 |
Family
ID=80447915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230402A CR20230402A (es) | 2021-01-19 | 2022-01-19 | Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4281078A1 (es) |
JP (1) | JP2024502886A (es) |
KR (1) | KR20230137368A (es) |
CN (1) | CN116723843A (es) |
AU (1) | AU2022210517A1 (es) |
CA (1) | CA3203205A1 (es) |
CL (1) | CL2023002071A1 (es) |
CO (1) | CO2023010777A2 (es) |
CR (1) | CR20230402A (es) |
EC (1) | ECSP23053891A (es) |
IL (1) | IL304294A (es) |
WO (1) | WO2022157629A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023165438A1 (zh) * | 2022-03-03 | 2023-09-07 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
CN115448925B (zh) * | 2022-09-16 | 2023-08-04 | 上海交通大学医学院附属第九人民医院 | 九氟卡马替尼及其盐的制备方法和用途 |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
CN116478141B (zh) * | 2023-06-20 | 2023-10-24 | 药康众拓(江苏)医药科技有限公司 | 氘代kras抑制剂药物及用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL1016759C2 (nl) | 2000-11-30 | 2002-05-31 | Jean Jacques Van Hartesveldt | Rolschaats voorzien van een rem. |
US8039506B2 (en) | 2006-12-20 | 2011-10-18 | Bristol-Myers Squibb Company | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants |
TWI434690B (zh) | 2007-12-19 | 2014-04-21 | Dainippon Sumitomo Pharma Co | 雜雙環衍生物 |
CN102633812B (zh) * | 2012-04-06 | 2014-11-12 | 中国药科大学 | 噁唑酮并喹唑啉衍生物、制备方法及用途 |
CN106414442B (zh) | 2014-04-23 | 2019-03-15 | 因赛特公司 | 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮 |
US10913753B2 (en) | 2016-02-12 | 2021-02-09 | Valo Early Discovery, Inc. | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors |
CN105884699B (zh) | 2016-05-11 | 2019-05-07 | 中国药科大学 | 4-取代苯胺喹唑啉类衍生物及其制备方法和用途 |
WO2018115380A1 (en) | 2016-12-22 | 2018-06-28 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
PE20211444A1 (es) | 2017-12-13 | 2021-08-05 | Lupin Ltd | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 |
LT3728254T (lt) * | 2017-12-21 | 2023-05-10 | Boehringer Ingelheim International Gmbh | Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai |
CN114375202A (zh) | 2019-06-19 | 2022-04-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras抑制劑 |
CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022008066A (es) * | 2019-12-27 | 2022-08-15 | Lupin Ltd | Compuestos triciclicos sustituidos. |
WO2021259972A1 (en) | 2020-06-24 | 2021-12-30 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor |
-
2022
- 2022-01-19 AU AU2022210517A patent/AU2022210517A1/en active Pending
- 2022-01-19 CA CA3203205A patent/CA3203205A1/en active Pending
- 2022-01-19 WO PCT/IB2022/050415 patent/WO2022157629A1/en active Application Filing
- 2022-01-19 EP EP22703706.6A patent/EP4281078A1/en active Pending
- 2022-01-19 CR CR20230402A patent/CR20230402A/es unknown
- 2022-01-19 JP JP2023543184A patent/JP2024502886A/ja active Pending
- 2022-01-19 KR KR1020237028163A patent/KR20230137368A/ko unknown
- 2022-01-19 CN CN202280010685.0A patent/CN116723843A/zh active Pending
-
2023
- 2023-07-06 IL IL304294A patent/IL304294A/en unknown
- 2023-07-17 CL CL2023002071A patent/CL2023002071A1/es unknown
- 2023-07-18 EC ECSENADI202353891A patent/ECSP23053891A/es unknown
- 2023-08-17 CO CONC2023/0010777A patent/CO2023010777A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3203205A1 (en) | 2022-07-28 |
CN116723843A (zh) | 2023-09-08 |
JP2024502886A (ja) | 2024-01-23 |
KR20230137368A (ko) | 2023-10-04 |
ECSP23053891A (es) | 2023-08-31 |
WO2022157629A1 (en) | 2022-07-28 |
EP4281078A1 (en) | 2023-11-29 |
IL304294A (en) | 2023-09-01 |
CL2023002071A1 (es) | 2024-02-09 |
AU2022210517A1 (en) | 2023-07-27 |
CO2023010777A2 (es) | 2023-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230402A (es) | Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer | |
da Costa et al. | Targeting replication stress in cancer therapy | |
Sun et al. | A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma | |
García-Gómez et al. | Protein–protein interactions: Emerging oncotargets in the RAS-ERK pathway | |
Knight et al. | Targeting the cancer kinome through polypharmacology | |
Sarkisian et al. | MEK inhibitors for the treatment of NRAS mutant melanoma | |
Choi et al. | Challenges in Ras therapeutics in pancreatic cancer | |
Schneider et al. | Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-Kit–Positive, Extensive-Stage Small-Cell Lung Cancer | |
Ladds et al. | Small molecule activators of the p53 response | |
Zhang | BRAF inhibitors: the current and the future | |
Tatarian et al. | Genetics of pancreatic cancer and its implications on therapy | |
London | Small molecule inhibitors in veterinary oncology practice | |
Meulendijks et al. | Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study | |
Shimomura et al. | Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer | |
Luke et al. | The biology and clinical development of MEK inhibitors for cancer | |
Halsey et al. | Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor | |
Davies et al. | Targeted therapy for melanoma: a primer | |
Miyake et al. | 5‑fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma | |
DK2948137T3 (en) | METHODS OF TREATING FIBROSE AND CANCER TYPES | |
Londhe et al. | Targeted therapies in veterinary oncology | |
Morin-Ben Abdallah et al. | Epidermal growth factor receptor tyrosine kinase inhibitors in treatment of metastatic non-small cell lung cancer, with a focus on afatinib | |
De Pauw et al. | Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer | |
Gupta et al. | Identification of synergistic drug combinations to target KRAS-driven chemoradioresistant cancers utilizing tumoroid models of colorectal adenocarcinoma and recurrent glioblastoma | |
Torino et al. | The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer | |
Longo | Cancer-drug discovery? Let's get ready for the next period |